FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306291409> ?p ?o ?g. }

• W4306291409 abstract "Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a major health problem associated with substantial morbidity and mortality. However, the underlying pathophysiological mechanisms are poorly understood, and effective treatment strategies are scarce. Importantly, SGLT2i, which have been suggested to improve cellular Na and Ca homeostasis in HFrEF, have recently been shown to also improve clinical outcomes in patients with HFpEF. Interestingly, post-hoc analyses of clinical data suggest an involvement of anti-arrhythmic effects of SGLT2i. Purpose We tested, if isolated human atrial cardiomyocytes from patients with HFpEF exhibit an increased Na influx that is responsive to treatment with the SGLT2i empagliflozin (Empa) and if Empa has anti-arrhythmic properties in human atrial trabeculae. Methods Atrial biopsies were obtained from 101 patients undergoing elective cardiac surgery. Na influx was measured as increase in [Na]i during Na/K-ATPase inhibition in isolated cardiomyocytes loaded with the Na-sensitive fluorescence dye Asante Natrium Green–2 AM (ANG-2). Western Blot and HDAC4 pulldown assay were used to investigate NaV1.5 expression/phosphorylation as well as CaMKII expression/autophosphorylation and activity. Anti-arrhythmic effects of Empa were evaluated as the reduction in premature atrial complexes (PACs), which were induced in electrically field-stimulated (1Hz) human atrial trabeculae by superfusion with isoproterenol (100 nM) and high Ca (3.5 mM). Results Compared to patients without heart failure (NF), Na influx was almost doubled in HFpEF patients (NF vs HFpEF: 0.21±0.02 vs 0.38±0.04 mmol/L/min (N=7 vs 18); p=0.005) (Fig. 1D, E). CaMKII expression, CaMKII autophosphorylation, CaMKII activity, and CaMKII-dependent NaV1.5 phosphorylation were significantly increased in atrial biopsies of HFpEF patients, whereas NaV1.5 protein abundance remained unchanged (Fig. 1A–C). Consistent with these results, the increased Na influx was significantly reduced by treatment with the specific CaMKII inhibitor autocamtide-2 related inhibitory peptide (AIP) and the late INa inhibitor tetrodotoxin (TTX) (Fig. 1D, E). Importantly, Empa also abolished the increased Na influx in HFpEF cardiomyocytes (Fig. 1D, E). Multivariate linear regression analysis, adjusting for clinical co-variates, revealed HFpEF to be an independent predictor of cardiomyocyte Na handling. In line with Empa-mediated inhibition of Na influx, the frequency of PACs in human atrial trabeculae was significantly reduced by Empa (Fig. 1F, G). Conclusion This is the first study to demonstrate increased Na influx in human cardiomyocytes from HFpEF patients potentially by an increased CaMKII-dependent NaV1.5 phosphorylation. Excitingly, treatment with Empa decreases this Na influx in HFpEF cardiomyocytes and reduces isoproterenol-induced arrhythmic activity in human atrial trabeculae, which could contribute to the cardioprotective effects of this drug in patients with HFpEF. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Else Kröner-Fresenius-Stiftung,Deutsche Forschungsgemeinschaft" @default.
• W4306291409 created "2022-10-15" @default.
• W4306291409 creator A5022333047 @default.
• W4306291409 creator A5031613370 @default.
• W4306291409 creator A5041301910 @default.
• W4306291409 creator A5043850692 @default.
• W4306291409 creator A5048581698 @default.
• W4306291409 creator A5057028576 @default.
• W4306291409 creator A5057272436 @default.
• W4306291409 creator A5067011173 @default.
• W4306291409 creator A5067074295 @default.
• W4306291409 creator A5068154165 @default.
• W4306291409 creator A5073325432 @default.
• W4306291409 creator A5077967848 @default.
• W4306291409 date "2022-10-01" @default.
• W4306291409 modified "2023-09-23" @default.
• W4306291409 title "Empagliflozin inhibits increased Na influx in HFpEF cardiomyocytes and reduces arrhythmic activity in human atrial trabeculae" @default.
• W4306291409 doi "https://doi.org/10.1093/eurheartj/ehac544.2948" @default.
• W4306291409 hasPublicationYear "2022" @default.
• W4306291409 type Work @default.
• W4306291409 citedByCount "0" @default.
• W4306291409 crossrefType "journal-article" @default.
• W4306291409 hasAuthorship W4306291409A5022333047 @default.
• W4306291409 hasAuthorship W4306291409A5031613370 @default.
• W4306291409 hasAuthorship W4306291409A5041301910 @default.
• W4306291409 hasAuthorship W4306291409A5043850692 @default.
• W4306291409 hasAuthorship W4306291409A5048581698 @default.
• W4306291409 hasAuthorship W4306291409A5057028576 @default.
• W4306291409 hasAuthorship W4306291409A5057272436 @default.
• W4306291409 hasAuthorship W4306291409A5067011173 @default.
• W4306291409 hasAuthorship W4306291409A5067074295 @default.
• W4306291409 hasAuthorship W4306291409A5068154165 @default.
• W4306291409 hasAuthorship W4306291409A5073325432 @default.
• W4306291409 hasAuthorship W4306291409A5077967848 @default.
• W4306291409 hasBestOaLocation W43062914091 @default.
• W4306291409 hasConcept C126322002 @default.
• W4306291409 hasConcept C134018914 @default.
• W4306291409 hasConcept C164705383 @default.
• W4306291409 hasConcept C2775887513 @default.
• W4306291409 hasConcept C2777099384 @default.
• W4306291409 hasConcept C2777180221 @default.
• W4306291409 hasConcept C2778198053 @default.
• W4306291409 hasConcept C555293320 @default.
• W4306291409 hasConcept C71924100 @default.
• W4306291409 hasConcept C78085059 @default.
• W4306291409 hasConceptScore W4306291409C126322002 @default.
• W4306291409 hasConceptScore W4306291409C134018914 @default.
• W4306291409 hasConceptScore W4306291409C164705383 @default.
• W4306291409 hasConceptScore W4306291409C2775887513 @default.
• W4306291409 hasConceptScore W4306291409C2777099384 @default.
• W4306291409 hasConceptScore W4306291409C2777180221 @default.
• W4306291409 hasConceptScore W4306291409C2778198053 @default.
• W4306291409 hasConceptScore W4306291409C555293320 @default.
• W4306291409 hasConceptScore W4306291409C71924100 @default.
• W4306291409 hasConceptScore W4306291409C78085059 @default.
• W4306291409 hasIssue "Supplement_2" @default.
• W4306291409 hasLocation W43062914091 @default.
• W4306291409 hasOpenAccess W4306291409 @default.
• W4306291409 hasPrimaryLocation W43062914091 @default.
• W4306291409 hasRelatedWork W2061321770 @default.
• W4306291409 hasRelatedWork W2965474825 @default.
• W4306291409 hasRelatedWork W3033076790 @default.
• W4306291409 hasRelatedWork W3157316619 @default.
• W4306291409 hasRelatedWork W3165187768 @default.
• W4306291409 hasRelatedWork W3214641872 @default.
• W4306291409 hasRelatedWork W4229334242 @default.
• W4306291409 hasRelatedWork W4303476234 @default.
• W4306291409 hasRelatedWork W4309074402 @default.
• W4306291409 hasRelatedWork W4313824657 @default.
• W4306291409 hasVolume "43" @default.
• W4306291409 isParatext "false" @default.
• W4306291409 isRetracted "false" @default.
• W4306291409 workType "article" @default.